Annual CFI
$14.98 M
+$30.66 M+195.50%
31 December 2023
Summary:
Oncolytics Biotech annual cash flow from investing activities is currently $14.98 million, with the most recent change of +$30.66 million (+195.50%) on 31 December 2023. During the last 3 years, it has risen by +$15.00 million (+69435.19%). ONCY annual CFI is now at all-time high.ONCY Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
N/A
30 September 2024
Summary:
Oncolytics Biotech quarterly cash flow from investing activities is not available.ONCY Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
N/A
30 September 2024
Summary:
Oncolytics Biotech TTM cash flow from investing activities is not available.ONCY TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ONCY Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +195.5% | - | - |
| 3 y3 years | +10000.0% | - | - |
| 5 y5 years | +10000.0% | - | - |
ONCY Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +195.5% | ||||
| 5 y | 5 years | at high | +195.5% | ||||
| alltime | all time | at high | +195.5% |
Oncolytics Biotech Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $14.98 M(-195.5%) | -$94.10 K(-101.9%) | $14.98 M(-2733.0%) |
| Sept 2023 | - | $5.07 M(-0.2%) | -$568.80 K(-89.9%) |
| June 2023 | - | $5.08 M(+3.0%) | -$5.64 M(-47.4%) |
| Mar 2023 | - | $4.93 M(-131.5%) | -$10.72 M(-31.6%) |
| Dec 2022 | -$15.68 M(+6775.1%) | -$15.64 M(>+9900.0%) | -$15.68 M(>+9900.0%) |
| Sept 2022 | - | -$6100.00(-27.4%) | -$103.30 K(-60.2%) |
| June 2022 | - | -$8400.00(-70.4%) | -$259.50 K(+1.2%) |
| Mar 2022 | - | -$28.40 K(-53.0%) | -$256.50 K(+12.5%) |
| Dec 2021 | -$228.10 K(+956.0%) | -$60.40 K(-62.8%) | -$228.10 K(+36.3%) |
| Sept 2021 | - | -$162.30 K(+2905.6%) | -$167.40 K(+873.3%) |
| June 2021 | - | -$5400.00(<-9900.0%) | -$17.20 K(+25.5%) |
| Mar 2021 | - | $0.00(-100.0%) | -$13.70 K(-36.9%) |
| Dec 2020 | -$21.60 K(+163.4%) | $300.00(-102.5%) | -$21.70 K(-5.2%) |
| Sept 2020 | - | -$12.10 K(+536.8%) | -$22.90 K(+110.1%) |
| June 2020 | - | -$1900.00(-76.3%) | -$10.90 K(-22.7%) |
| Mar 2020 | - | -$8000.00(+788.9%) | -$14.10 K(+72.0%) |
| Dec 2019 | -$8200.00(-90.1%) | -$900.00(+800.0%) | -$8200.00(-582.4%) |
| Sept 2019 | - | -$100.00(-98.0%) | $1700.00(-106.0%) |
| June 2019 | - | -$5100.00(+142.9%) | -$28.10 K(-45.2%) |
| Mar 2019 | - | -$2100.00(-123.3%) | -$51.30 K(-38.1%) |
| Dec 2018 | -$82.90 K(-105.4%) | $9000.00(-130.1%) | -$82.90 K(-45.5%) |
| Sept 2018 | - | -$29.90 K(+5.7%) | -$152.10 K(+634.8%) |
| June 2018 | - | -$28.30 K(-16.0%) | -$20.70 K(-72.9%) |
| Mar 2018 | - | -$33.70 K(-44.0%) | -$76.50 K(-105.0%) |
| Dec 2017 | $1.53 M(-4043.6%) | -$60.20 K(-159.3%) | $1.53 M(-3.2%) |
| Sept 2017 | - | $101.50 K(-220.7%) | $1.58 M(+7.1%) |
| June 2017 | - | -$84.10 K(-105.3%) | $1.48 M(-5.0%) |
| Mar 2017 | - | $1.57 M(<-9900.0%) | $1.55 M(-4106.2%) |
| Dec 2016 | -$38.80 K(-64.0%) | -$9400.00(+176.5%) | -$38.80 K(-50.6%) |
| Sept 2016 | - | -$3400.00(-40.4%) | -$78.60 K(-8.4%) |
| June 2016 | - | -$5700.00(-71.9%) | -$85.80 K(-9.4%) |
| Mar 2016 | - | -$20.30 K(-58.7%) | -$94.70 K(-12.1%) |
| Dec 2015 | -$107.80 K(-34.9%) | -$49.20 K(+364.2%) | -$107.70 K(+41.3%) |
| Sept 2015 | - | -$10.60 K(-27.4%) | -$76.20 K(-55.2%) |
| June 2015 | - | -$14.60 K(-56.2%) | -$170.20 K(+8.3%) |
| Mar 2015 | - | -$33.30 K(+88.1%) | -$157.20 K(-5.1%) |
| Dec 2014 | -$165.60 K(-40.6%) | -$17.70 K(-83.1%) | -$165.60 K(+7.4%) |
| Sept 2014 | - | -$104.60 K(+6437.5%) | -$154.20 K(+5.2%) |
| June 2014 | - | -$1600.00(-96.2%) | -$146.60 K(-46.4%) |
| Mar 2014 | - | -$41.70 K(+561.9%) | -$273.50 K(-2.0%) |
| Dec 2013 | -$279.00 K(+75.6%) | -$6300.00(-93.5%) | -$279.00 K(-0.3%) |
| Sept 2013 | - | -$97.00 K(-24.5%) | -$279.70 K(+33.3%) |
| June 2013 | - | -$128.50 K(+172.2%) | -$209.80 K(+47.9%) |
| Mar 2013 | - | -$47.20 K(+574.3%) | -$141.90 K(-10.8%) |
| Dec 2012 | -$158.90 K(-111.1%) | -$7000.00(-74.2%) | -$159.00 K(-50.8%) |
| Sept 2012 | - | -$27.10 K(-55.3%) | -$323.40 K(-14.7%) |
| June 2012 | - | -$60.60 K(-5.8%) | -$379.10 K(-127.4%) |
| Mar 2012 | - | -$64.30 K(-62.5%) | $1.38 M(-3.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | $1.43 M(-171.5%) | -$171.40 K(+107.0%) | $1.43 M(-5.2%) |
| Sept 2011 | - | -$82.80 K(-104.9%) | $1.51 M(-653.3%) |
| June 2011 | - | $1.70 M(<-9900.0%) | -$272.80 K(-86.4%) |
| Mar 2011 | - | -$15.50 K(-83.3%) | -$2.01 M(+0.6%) |
| Dec 2010 | -$2.00 M(-154.6%) | -$92.70 K(-95.0%) | -$2.00 M(-44.0%) |
| Sept 2010 | - | -$1.86 M(+4706.7%) | -$3.57 M(+154.7%) |
| June 2010 | - | -$38.80 K(+1008.6%) | -$1.40 M(-378.3%) |
| Mar 2010 | - | -$3500.00(-99.8%) | $504.00 K(-86.2%) |
| Dec 2009 | $3.66 M(-69.0%) | -$1.67 M(-646.3%) | $3.66 M(-746.9%) |
| Sept 2009 | - | $304.80 K(-83.7%) | -$565.80 K(-106.9%) |
| June 2009 | - | $1.87 M(-40.8%) | $8.23 M(-27.7%) |
| Mar 2009 | - | $3.15 M(-153.5%) | $11.38 M(-3.7%) |
| Dec 2008 | $11.81 M(+169.9%) | -$5.89 M(-164.7%) | $11.81 M(-49.5%) |
| Sept 2008 | - | $9.10 M(+81.3%) | $23.40 M(+73.8%) |
| June 2008 | - | $5.02 M(+40.1%) | $13.46 M(+60.7%) |
| Mar 2008 | - | $3.58 M(-37.1%) | $8.38 M(+91.4%) |
| Dec 2007 | $4.38 M(-58.3%) | $5.70 M(-777.8%) | $4.38 M(+226.0%) |
| Sept 2007 | - | -$840.20 K(+1223.1%) | $1.34 M(-24.5%) |
| June 2007 | - | -$63.50 K(-84.7%) | $1.78 M(-67.1%) |
| Mar 2007 | - | -$415.30 K(-115.6%) | $5.40 M(-48.5%) |
| Dec 2006 | $10.49 M(-176.4%) | $2.66 M(-759.1%) | $10.49 M(-446.0%) |
| Sept 2006 | - | -$403.80 K(-111.3%) | -$3.03 M(-0.4%) |
| June 2006 | - | $3.56 M(-23.8%) | -$3.04 M(-38.3%) |
| Mar 2006 | - | $4.67 M(-143.0%) | -$4.93 M(-64.1%) |
| Dec 2005 | -$13.73 M(+295.9%) | -$10.85 M(+2515.6%) | -$13.73 M(+481.9%) |
| Sept 2005 | - | -$415.00 K(-124.9%) | -$2.36 M(-2.6%) |
| June 2005 | - | $1.67 M(-140.5%) | -$2.42 M(-70.3%) |
| Mar 2005 | - | -$4.13 M(-904.3%) | -$8.17 M(+135.5%) |
| Dec 2004 | -$3.47 M(-70.1%) | $513.10 K(-207.3%) | -$3.47 M(-56.8%) |
| Sept 2004 | - | -$478.00 K(-88.3%) | -$8.04 M(-51.2%) |
| June 2004 | - | -$4.07 M(-812.0%) | -$16.47 M(+53.7%) |
| Mar 2004 | - | $572.30 K(-114.1%) | -$10.72 M(-7.6%) |
| Dec 2003 | -$11.59 M(+1416.7%) | -$4.05 M(-54.5%) | -$11.59 M(+49.6%) |
| Sept 2003 | - | -$8.91 M(-631.8%) | -$7.75 M(-1038.8%) |
| June 2003 | - | $1.68 M(-649.8%) | $825.50 K(-194.2%) |
| Mar 2003 | - | -$304.70 K(+44.7%) | -$876.30 K(+14.6%) |
| Dec 2002 | -$764.40 K(+102.1%) | -$210.60 K(-37.0%) | -$764.40 K(+18.5%) |
| Sept 2002 | - | -$334.50 K(+1162.3%) | -$644.90 K(+32.2%) |
| June 2002 | - | -$26.50 K(-86.3%) | -$487.70 K(-10.6%) |
| Mar 2002 | - | -$192.80 K(+111.6%) | -$545.60 K(+44.3%) |
| Dec 2001 | -$378.20 K(+50.6%) | -$91.10 K(-48.6%) | -$378.20 K(+6.6%) |
| Sept 2001 | - | -$177.30 K(+110.1%) | -$354.70 K(+58.0%) |
| June 2001 | - | -$84.40 K(+232.3%) | -$224.50 K(+8.5%) |
| Mar 2001 | - | -$25.40 K(-62.4%) | -$206.90 K(-17.6%) |
| Dec 2000 | -$251.10 K(+430.9%) | -$67.60 K(+43.5%) | -$251.10 K(+36.8%) |
| Sept 2000 | - | -$47.10 K(-29.5%) | -$183.50 K(+34.5%) |
| June 2000 | - | -$66.80 K(-4.0%) | -$136.40 K(+96.0%) |
| Mar 2000 | - | -$69.60 K | -$69.60 K |
| Dec 1999 | -$47.30 K | - | - |
FAQ
- What is Oncolytics Biotech annual cash flow from investing activities?
- What is the all time high annual CFI for Oncolytics Biotech?
- What is Oncolytics Biotech annual CFI year-on-year change?
- What is the all time high quarterly CFI for Oncolytics Biotech?
- What is the all time high TTM CFI for Oncolytics Biotech?
What is Oncolytics Biotech annual cash flow from investing activities?
The current annual CFI of ONCY is $14.98 M
What is the all time high annual CFI for Oncolytics Biotech?
Oncolytics Biotech all-time high annual cash flow from investing activities is $14.98 M
What is Oncolytics Biotech annual CFI year-on-year change?
Over the past year, ONCY annual cash flow from investing activities has changed by +$30.66 M (+195.50%)
What is the all time high quarterly CFI for Oncolytics Biotech?
Oncolytics Biotech all-time high quarterly cash flow from investing activities is $9.10 M
What is the all time high TTM CFI for Oncolytics Biotech?
Oncolytics Biotech all-time high TTM cash flow from investing activities is $23.40 M